

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 148044 Jie Yu Fang a.k.a. Mood-Uplift 2 Formula

ARTG entry for Medicine Listed

Sponsor Sun Herbal Pty Ltd

Postal Address Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208

Australia

ARTG Start Date 4/12/2007

Product Category Medicine

Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Jie Yu Fang a.k.a. Mood-Uplift 2 Formula

Product Type Single Medicine Product Effective Date 31/05/2018

Permitted Indications

Traditionally used in Chinese medicine to open body orifices

Traditionally used in Chinese medicine to regulate Qi

Traditionally used in Chinese medicine to nourish the heart

Traditionally used in Chinese medicine to calm/soothe/nourish the liver

Traditionally used in Chinese medicine to calm/soothe/nourish/balance spirit

Traditionally used in Chinese medicine to clear/expel/dissolve/resolve Phlegm

Indication Requirements

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Page 1 of 2



Australian Government

Department of Health

Therapeutic Goods Administration

Warnings

For practitioner dispensing only.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Anemone altaica rhizome Extract dry concentrate	13.32 mg
Equivalent: Anemone altaica (Dry)	79.92 mg
Angelica polymorpha root Extract dry concentrate	26.67 mg
Equivalent: Angelica polymorpha (Dry)	160.02 mg
Astragalus membranaceus root Extract dry concentrate	33.36 mg
Equivalent: Astragalus membranaceus (Dry)	200.16 mg
Bupleurum falcatum root Extract dry concentrate	20.01 mg
Equivalent: Bupleurum falcatum (Dry)	120.06 mg
Citrus reticulata fruit peel Extract dry concentrate	13.32 mg
Equivalent: Citrus reticulata (Dry)	79.92 mg
Curcuma longa tuber Extract dry concentrate	26.67 mg
Equivalent: Curcuma longa (Dry)	160.02 mg
Cyperus rotundus rhizome Extract dry concentrate	22.2 mg
Equivalent: Cyperus rotundus (Dry)	133.2 mg
Paeonia lactiflora root Extract dry concentrate	26.67 mg
Equivalent: Paeonia lactiflora (Dry)	160.02 mg
Phyllostachys nigra stem Extract dry concentrate	20.01 mg
Equivalent: Phyllostachys nigra (Dry)	120.06 mg
Pinellia ternata tuber Extract dry concentrate	26.67 mg
Equivalent: Pinellia ternata (Dry)	160.02 mg
Polygala sibirica root Extract dry concentrate	11.1 mg
Equivalent: Polygala sibirica (Dry)	66.6 mg
Pseudostellaria heterophylla root Extract dry concentrate	26.67 mg
Equivalent: Pseudostellaria heterophylla (Dry)	160.02 mg
Wolfiporia cocos fruiting body Extract dry concentrate	33.33 mg
Equivalent: Wolfiporia cocos (Dry)	199.98 mg

Other Ingredients (Excipients)

hydrolysed gelatin soluble maize starch titanium dioxide

[©] Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.